Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;62(9):730-738.
doi: 10.1111/myc.12958. Epub 2019 Jul 11.

Mucormycosis in South America: A review of 143 reported cases

Affiliations
Review

Mucormycosis in South America: A review of 143 reported cases

Marcio Nucci et al. Mycoses. 2019 Sep.

Abstract

Mucormycosis is a rare but important invasive fungal disease that most often affects immunocompromised hosts. The incidence of mucormycosis appears to be increasing worldwide, as risk factors such as the use of immunosuppressive therapies become more common. We report the results of a literature review of 143 mucormycosis cases reported in South America between 1960 and 2018. The number of reported cases has increased by decade, from 6 in the 1960s to 51 in the 2010s. The most common underlying conditions associated with mucormycosis in South America were diabetes mellitus (42.0%) and penetrating trauma/burns (20.0%). Underlying conditions involving immunosuppression, including treatment of haematologic malignancy, solid organ transplant, and corticosteroid use, also accounted for a large proportion of cases (45.5%). Between 1960 and 2018, cases of mucormycosis associated with conditions involving immunosuppression accounted for the highest mortality rate (58.5%), followed by diabetes mellitus (45.0%), and penetrating trauma/burns (37.9%). Overall mortality decreased from 100% to 39.4% during this period, mainly driven by the increasing availability and use of antifungal therapies and surgical intervention. However, these treatments are not yet universally utilised across the region in the treatment of mucormycosis; efforts to improve availability of effective treatments would be likely to improve outcomes.

Keywords: Brazil; South America; antifungal agents; invasive fungal disease; mucormycosis; systemic infection.

PubMed Disclaimer

Conflict of interest statement

ME and KH are employees of Basilea Pharmaceutica International Ltd. MN has received honoraria from AbbVie, Astellas, Gilead, Janssen, Merck, Pfizer, Teva and United Medical.

Figures

Figure 1
Figure 1
Number of published cases of invasive mucormycosis reported in South America by decade since 1960, and corresponding mortality
Figure 2
Figure 2
Number of reported mucormycosis cases by site, separated according to underlying disease
Figure 3
Figure 3
Number and proportion of treatments for published cases of invasive mucormycosis reported in South America by decade since 1960. One patient in 1977 and two patients in 1991 underwent surgery without antifungal treatment

Similar articles

Cited by

References

    1. Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med. 2014;5(1):a019273. - PMC - PubMed
    1. Köhler JR, Hube B, Puccia R, Casadevall A, Perfect JR. Fungi that infect humans. Microbiol Spectr. 2017;5:3. - PMC - PubMed
    1. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556‐569. - PMC - PubMed
    1. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859‐1867. - PubMed
    1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23‐34. - PubMed

MeSH terms

Substances